Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.86 |
| ▸ | DRD4 | P21917 | 2/20 | 0.74 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.62 |
| ▸ | CCR3 | P51677 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4813917 | 0.99 | OPRL1 (0.84) | OPRL1DRD4CHRM4OPRM1OPRD1 | |
| SCHEMBL8891716 | 0.90 | OPRL1 (0.69) | OPRL1DRD4CHRM4OPRM1OPRD1 | |
| SCHEMBL2871398 | 0.87 | OPRL1 (0.68) | OPRL1DRD4CHRM4OPRM1OPRD1 | |
| SCHEMBL10954756 | 0.85 | OPRL1 (0.64) | OPRL1DRD4CHRM4OPRM1OPRD1 | |
| SCHEMBL4778246 | 0.85 | OPRL1 (0.78) | OPRL1DRD4OPRM1OPRD1POLB | |
| SCHEMBL699951 | 0.85 | OPRL1 (0.63) | OPRL1DRD4CHRM4OPRM1OPRD1 | |
| SCHEMBL4817542 | 0.85 | OPRL1 (0.62) | OPRL1DRD4CHRM4OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL11397626 | 0.84 | OPRL1 (0.63) | OPRL1DRD4CHRM4OPRM1OPRD1 | |
| SCHEMBL3126554 | 0.84 | OPRL1 (0.62) | OPRL1DRD4CHRM4OPRM1OPRD1 | |
| SCHEMBL3897322 | 0.83 | OPRL1 (0.73) | OPRL1DRD4OPRM1OPRD1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46117-E1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-08-23 | — | — | US | disclosed |
| EP-1773823-B1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-08-21 | — | — | EP | disclosed |
| CN-101006084-B | 4-arylmorpholin-3-one derivatives, preparation method and therapeutic use thereof | SANOFI AVENTIS | 2010-09-08 | — | — | CN | disclosed |
| EP-1699778-B1 | (4-PHENYLPIPERAZIN-1-YL)ACYLPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-07-14 | — | — | EP | disclosed |
| US-7521449-B2 | 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-04-21 | — | — | US | disclosed |
| CN-100448875-C | Substituted 1-piperazinoylpiperidine derivatives, their preparation and therapeutic use | SANOFI AVENTIS (FR) | 2009-01-07 | — | — | CN | disclosed |
| US-7468368-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-7417043-B2 | Modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2008-08-26 | — | — | US | disclosed |
| US-7294628-B2 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| CN-101006084-A | 4-arylmorpholin-3-one derivatives, preparation method and therapeutic use thereof | SANOFI AVENTIS (FR) | 2007-07-25 | — | — | CN | disclosed |
| EP-1428822-A2 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003104225-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104226-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2003-07-24 | — | — | US | disclosed |
| EP-1240142-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046145-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| US-5294619-A | N-(nitrogen-containing heterocyclylalkyl-phenyl-piperidines | PFIZER INC. (US) | 1994-03-15 | — | — | US | disclosed |
| US-5153206-A | Neuroleptic agents for treating psychological disorders | PFIZER INC. (US) | 1992-10-06 | — | — | US | disclosed |
| WO-1990006303-A1 | ARYLPIPERIDINE DERIVATIVES | PFIZER INC. (US) | 1990-06-14 | — | — | WO | disclosed |
| EP-0372776-A2 | Arylpiperidine derivatives | PFIZER INC. (US) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139423-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | OPRL1 7/4885DRD4 30/4885CHRM4 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.